Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

National Institutes of Health

aMoon Fund

Decheng Capital

Verily

Pacific 8 Ventures

Plum Alley Investments

Mayfield Fund

Brook Byers

Senator Investment Group

Foresite Capital

Greenspring Associates

Sixth Street Partners

Tachyon Ventures

Redmile Group

Bradley Horowitz

Mammoth Biosciences

Don’t miss this tutorial session with Agilent Technologies and Mammoth Biosciences! Join us for an informative afternoon, our own Wesley Addison will be presenting.
See you there! #Innovation #Science #TechTalk #Biotech

Today at Keystone Symposia on Molecular & Cellular Biology's Precision Genome Engineering conference, Mammoth Biosciences co-founder & CTO Janice Chen will present an update on “Developing in vivo Therapeutics with Ultracompact CRISPR Systems”. The talk will highlight our fundamental innovation on #ultracompact #crispr  cargo and progress towards unlocking in vivo delivery of next-generation gene editors beyond the liver.

We're #hiring a new Vice President, Technical Operations in Brisbane, California. Apply today or share this post with your network.

We're #hiring a new Vice President, Translational Sciences in Brisbane, California. Apply today or share this post with your network.

We're #hiring a new Principal Project Manager I - Drug Development/Therapeutics in Brisbane, California. Apply today or share this post with your network.

Jenny is an amazing leader that if you qualify for the role, you should apply.

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Analytics

Google Maps

WordPress

Global Site Tag

Omri Amirav-Drory

Ursheet Parikh

Jeff Huber

Lloyd Minor

Jennifer Doudna

Tejas Maniar

Maneesh Jain

Charles Chiu

Trevor Martin

Co-Founder and CEO

Co-Founder

Lucas Harrington

Cofounder & President of Therapeutics

Janice Chen

Co-Founder, Chief Technology Officer

Ted Tisch

Chief Operating Officer

Rachel Herder

Vice President of Intellectual Property (IP)

Gary Loeb

General Counsel

Jesus Ching

VP of R&D

United States Companies With Less Than $1B in Revenue (Top 10K)

San Francisco Bay Area Companies With More Than 10 Employees (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Companies With More Than $1M in Revenue (Top 10K)

Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions.  By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

Mammoth has also been working on developing a rapid COVID-19 test.

Series D - Mammoth Biosciences

Series C - Mammoth Biosciences

Grant - Mammoth Biosciences

Series B - Mammoth Biosciences

Series A - Mammoth Biosciences

Seed Round - Mammoth Biosciences

Pre Seed Round - Mammoth Biosciences

San Francisco

California

United States

North America

How biotech startups become unicorns

ASGCT 2024: Mammoth Sizes Up Genome Editing Opportunities

Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines

Regeneron signs Mammoth gene editing deal worth $100M upfront

Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery

Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences

Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth

A CRISPR-based diagnostic system that identifies specific nucleic acids indicating disease presence, providing results in an instrument-free format.

CRISPR-based precision editing for therapeutic applications, leveraging novel CRISPR-Cas enzymes for genome editing.

Identification of novel CRISPR systems and Cas proteins through a proprietary discovery platform, expanding the scope of CRISPR applications.

Thailand

Asia

Turkey

Europe

Russian Federation

India

HTML5

HubSpot Forms

Adobe Fonts

Wordpress

HubSpot Marketing Hub

Lead Flows

Google Drive

Google Fonts

jQuery

CRISPR is a biotechnology company known for its gene editing technology and applications in various fields.

CRISPR

DiaCarta is a biotechnology company specializing in molecular diagnostics and precision medicine solutions.

DiaCarta

Intellia is a biotechnology company focused on developing CRISPR/Cas9-based therapies for genetic diseases.

Intellia

Inscripta is a biotechnology company that provides gene editing tools and technologies for various applications.

Inscripta

Sherlock Biosciences is a biotechnology company known for its CRISPR-based molecular diagnostics platform.

Sherlock Biosciences

Arbor Biosciences is a biotechnology company specializing in genetic research and molecular biology solutions.

Arbor Biosciences

Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.

news impact assignment basic	general	Mar 5, 2024 2:45 AM	3eafd6a9
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 2:45 AM	bab4ba40
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	d17aa7eb
crunchbase profile	general	Nov 22, 2024 9:30 AM	f5e50d84
li profile	general	Mar 5, 2024 2:45 AM	0880918f
translate crunchbase fundingrounds	general	Nov 22, 2024 3:53 PM	0830b902
peers	general
news basic	general	Mar 5, 2024 2:45 AM	40730645
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BIO:MAMMOTH

Mammoth Biosciences